Vedolizumab Safety During Pregnancy and Lactation in a Patient with Ulcerative Colitis: A Case Report

References

• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389:1741–1755. doi:10.1016/S0140-6736
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770. doi:10.1016/S0140-6736
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Safety of new biologics (vedolizumab and ustekinumab) and small molecules (Tofacitinib) during pregnancy: a review. Drugs. 2020;80(11):1085–1100. PMID: 32562207. doi:10.1007/s40265-020-01346-4
   PubMed Web of Science ®Google Scholar
• Laube R, Paramsothy S, Leong RW. Review of pregnancy in Crohn’s disease and ulcerative colitis. Therap Adv Gastroenterol. 2021;14:17562848211016242. PMID: 34046084; PMCID: PMC8135214. doi:10.1177/17562848211016242
   Web of Science ®Google Scholar
• Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Inflamm Bowel Dis. 2019;25(4):627–641. PMID: 30821832. doi:10.1093/ibd/izz037
   PubMed Web of Science ®Google Scholar
• U.S. Food & drug administration. Available from: https://www.fda.gov/. Accessed May 15, 2023.
   Google Scholar
• Torres J, Chaparro M, Julsgaard M, et al. European crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis. 2023;17(1):1–27. PMID: 36005814. doi:10.1093/ecco-jcc/jjac115
   PubMed Web of Science ®Google Scholar
• Mitrova K, Pipek B, Bortlik M, et al.; Working Group. Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study. J Crohns Colitis. 2022;16(12):1808–1815. PMID: 35708729. doi:10.1093/ecco-jcc/jjac086
   PubMed Web of Science ®Google Scholar
• Wils P, Seksik P, Stefanescu C, et al. PREGNANCY-GETAID study group. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Aliment Pharmacol Ther. 2021;53(4):460–470. PMID: 33345331. doi:10.1111/apt.16192
   PubMed Web of Science ®Google Scholar
• Chaparro M, Donday MG, Abad-Santos F, et al. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therap Adv Gastroenterol. 2021;14:17562848211018097. PMID: 34158835; PMCID: PMC8182220. doi:10.1177/17562848211018097
   Web of Science ®Google Scholar
• Mahadevan U, Long MD, Kane SV, et al. Crohn’s colitis foundation clinical research alliance. pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160(4):1131–1139. PMID: 33227283; PMCID: PMC7956164. doi:10.1053/j.gastro.2020.11.038
   PubMed Web of Science ®Google Scholar
• Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129–138. PMID: 31692017. doi:10.1111/apt.15539
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(1):74–87.e3. PMID: 32931960. doi:10.1016/j.cgh.2020.09.021
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Kaplan GG, Bernstein CN, et al.; International Organization for Study of Inflammatory Bowel Diseases. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022;7(7):666–678. PMID: 35487235. doi:10.1016/S2468-1253(22)00021-8
   PubMed Web of Science ®Google Scholar
• Odufalu FD, Long M, Lin K, Mahadevan U. PIANO Investigators from the Crohn’s and Colitis Foundation (CCF) Clinical Research Alliance recruited patients for their respective centers for participant enrollment. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut. 2022;71(9):1766–1772. PMID: 34686575. doi:10.1136/gutjnl-2021-325317
   PubMed Web of Science ®Google Scholar
• Brondfield MN, Mahadevan U. Inflammatory bowel disease in pregnancy and breastfeeding. Nat Rev Gastroenterol Hepatol. 2023;20(8):504–523. PMID: 37002407. doi:10.1038/s41575-023-00758-3
   PubMed Web of Science ®Google Scholar
• Chugh R, Long MD, Jiang Y, et al. Maternal and neonatal outcomes in vedolizumab and ustekinumab exposed pregnancies: results from the PIANO registry. Am J Gastroenterol. 2023. PMID: 37796648. doi:10.14309/ajg.0000000000002553
   PubMed Web of Science ®Google Scholar
• Flanagan E, Gibson PR, Wright EK, et al. Infliximab, Adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52(10):1551–1562. PMID: 32981127. doi:10.1111/apt.16102
   PubMed Web of Science ®Google Scholar
• Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2021;20(3):275–292. PMID: 33412078. doi:10.1080/14740338.2021.1873948
   PubMed Web of Science ®Google Scholar
• Shmidt E, Dubinsky MC. Inflammatory bowel disease and pregnancy. Am J Gastroenterol. 2022;117(10S):60–68. PMID: 36194035. doi:10.14309/ajg.0000000000001963
   PubMed Web of Science ®Google Scholar